TY - JOUR
T1 - X-ray repair cross-complementing group 1 (XRCC1) single-nucleotide polymorphisms and the risk of salivary gland carcinomas
AU - Ho, Tang
AU - Li, Guojun
AU - Lu, Jiachun
AU - Zhao, Chong
AU - Wei, Qingyi
AU - Sturgis, Erich M.
PY - 2007/7/15
Y1 - 2007/7/15
N2 - BACKGROUND. X-ray repair cross complementing group 1 (XRCC1) is important in the repair of single-strand DNA breaks caused by endogenous oxidative species and exogenous carcinogens. METHODS. This tertiary cancer center-based, case-control association study included 138 patients with salivary gland carcinoma (SGC), 50 patients with benign salivary gland tumors, and a group of 503 cancer-free control participants. Polymerase chain reaction-restriction fragment length polymorphism genotyping assays were performed on 6 XRCC1 single-nucleotide polymorphisms (SNPs). Odds ratios (ORs) and 95% confidence intervals (95% CIs) were calculated in multivariate logistic regression analyses, and haplotype distributions were estimated. RESULTS. The XRCC1 genotype distributions of patients with SGC and control participants differed significantly for both the T1915C promoter SNP (P = .047) and the Arg194Trp coding region SNP (P = .037). The polymorphic 1915C allele was significantly less frequent in patients with SGC than in the controls (34% vs 42%; P = .031). Multivariate analysis demonstrated that individuals who had the 1915 polymorphic homozygous CC genotype (OR, 0.4; 95% CI, 0.2-0.9; P = .017) had a significantly lower risk of SGC, and individuals who had the Arg194Trp heterozygous CT genotype (OR, 1.6; 95% CI, 1.0-2.6; P = .059) had a higher, borderline significant risk. The CGTTGG haplotype was associated with a higher SGC risk (OR, 3.5; 95% CI, 1.1-11.3; P = .036). No findings were significant for the patients who had benign salivary gland tumors. CONCLUSIONS. In this study, the XRCC1 1915C allele was associated with a lower SGC risk, and the XRCC1 194Trp allele was associated with a higher SGC risk.
AB - BACKGROUND. X-ray repair cross complementing group 1 (XRCC1) is important in the repair of single-strand DNA breaks caused by endogenous oxidative species and exogenous carcinogens. METHODS. This tertiary cancer center-based, case-control association study included 138 patients with salivary gland carcinoma (SGC), 50 patients with benign salivary gland tumors, and a group of 503 cancer-free control participants. Polymerase chain reaction-restriction fragment length polymorphism genotyping assays were performed on 6 XRCC1 single-nucleotide polymorphisms (SNPs). Odds ratios (ORs) and 95% confidence intervals (95% CIs) were calculated in multivariate logistic regression analyses, and haplotype distributions were estimated. RESULTS. The XRCC1 genotype distributions of patients with SGC and control participants differed significantly for both the T1915C promoter SNP (P = .047) and the Arg194Trp coding region SNP (P = .037). The polymorphic 1915C allele was significantly less frequent in patients with SGC than in the controls (34% vs 42%; P = .031). Multivariate analysis demonstrated that individuals who had the 1915 polymorphic homozygous CC genotype (OR, 0.4; 95% CI, 0.2-0.9; P = .017) had a significantly lower risk of SGC, and individuals who had the Arg194Trp heterozygous CT genotype (OR, 1.6; 95% CI, 1.0-2.6; P = .059) had a higher, borderline significant risk. The CGTTGG haplotype was associated with a higher SGC risk (OR, 3.5; 95% CI, 1.1-11.3; P = .036). No findings were significant for the patients who had benign salivary gland tumors. CONCLUSIONS. In this study, the XRCC1 1915C allele was associated with a lower SGC risk, and the XRCC1 194Trp allele was associated with a higher SGC risk.
KW - Case-control studies
KW - DNA repair
KW - Genetic polymorphisms
KW - Humans
KW - Salivary gland neoplasms
UR - http://www.scopus.com/inward/record.url?scp=34547173791&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=34547173791&partnerID=8YFLogxK
U2 - 10.1002/cncr.22794
DO - 10.1002/cncr.22794
M3 - Article
C2 - 17559126
AN - SCOPUS:34547173791
SN - 0008-543X
VL - 110
SP - 318
EP - 325
JO - Cancer
JF - Cancer
IS - 2
ER -